A phase 1/2 clinical trial assessing Novavax’s (NASDAQ:NVAX) recombinant flu vaccine NanoFlu in older adults showed a treatment effect over and above the leading egg-based flu vaccine.

In three H3N2 strains, which accounted for ~3/4 of flu-related hospitalizations this year, NanoFlu produced 47 – 64% higher antibody titers compared to the egg-based high-dose vaccine.

The company expects to launch a Phase 2 study in Q3.

Pre clinical results show superior efficacy to current vaccines, for treating both extant and drifted flu strains.

Novavax continues to trade at a steep discount to its true value; major upcoming catalysts should lift it significantly higher.

sent the stock reeling to a 52-week low.

Novavax Inc. (NASDAQ:NVAX) soared to a new 52-week high on Mar. 1, 2018, following positive top-line results from its phase I/II clinical trial of its NanoFlu recombinant influenza vaccine in older adults.

The healthcare analyst’s have given positive outlook so far for Novavax comparing it to other in the same field below:

Recro Pharma (NASDAQ:REPH) resumed with Outperform rating and $19 (111% upside) price target at Oppenheimer.

Health Insurance Innovations (NASDAQ:HIIQ) upgraded to Outperform at Raymond James.

Surmodics (NASDAQ:SRDX) upgraded to Outperform at Barrington Research.

Novavax (NASDAQ:NVAX) upgraded to Buy at Citigroup.

Fulgent Genetics (NASDAQ:FLGT) downgraded to Neutral at Piper Jaffray.

Cross Country Healthcare (NASDAQ:CCRN) downgraded to Hold at Benchmark.

Portola Pharmaceuticals (NASDAQ:PTLA) downgraded to Equal Weight at Morgan Stanley. Price target cut to $30 (29% downside risk) from $65.

CWEB Analyst’s have initiated a Hold Rating for Novavax (NASDAQ:NVAX) and a Price Target of $3 within 6 months.

Read Full Article and Videos CWEB.com – Trending News, Blog, Shopping

NVAX data by YCharts